ORDINAL
Bristol Myers Advances Opdualag into Phase 3 Trials for First-Line Lung Cancer
Opdualag, Bristol Myers Squibb, lung cancer, first-line treatment, phase 3 trials, LAG-3/PD-1 combination therapy
F2G Secures $100M Funding for Second Attempt at FDA Approval for Novel Antifungal Drug Olorofim
F2G, antifungal drug, olorofim, FDA approval, funding, second attempt
Carisma Therapeutics to Lay Off Staff, Discontinue CAR-M Programs in Pursuit of Second Candidate
Carisma Therapeutics, Layoffs, Workforce reduction (37%), Dropping clinical CAR-M program, Anti-HER2 CAR-macrophage CT-0508, Anti-mesothelin CAR-monocyte candidate CT-1119, Second candidate focus
FDA Greenlights Opdivo Combination Therapy for First-Line Bladder Cancer Treatment
Overall Survival, Combined, cisplatin, Opdivo
GSK Boosts Blenrep’s Resurgence with Successful Second Phase III Trial
– **Company**: GlaxoSmithKline (GSK) – **Product**: Blenrep – **News**: Positive data reported from a second Phase III clinical trial for Blenrep – **Comeback Potential**: This news suggests a potential rebound for Blenrep, which previously faced setbacks – **Date**: Information released on March 15, 2024
FDA Approves Amtagvi as the First One-time Cell Therapy for Solid Tumors: A Groundbreaking TIL Immunotherapy for Advanced Melanoma
Amtagvi, Solid Neoplasm, United States Food and Drug Administration, Lymphocytes, Tumor-Infiltrating
Eicos Sciences’ Aurlumyn: First FDA-Approved Treatment for Severe Frostbite Reduces Amputation Risk
Aurlumyn, Eicos, Amputation, Sciences’, iloprost, severe frostbite
Eli Lilly says its potential gene therapy ‘restored hearing’ in 11-year-old boy
Hearing, Eli, Boys, 11-year-old
Lillys Investigational Gene Therapy Restores Hearing in First Treated Patient
Hearing, Treating, gene therapy, AK-OTOF